4 reports

GIVEN THAT CLL CELLS HAVE ELEVATED BASELINE LEVELS OF CHECKPOINT INHIBITORY MOLECULES COMPARED TO NONCANCEROUS CELLS, SUCH AS PD-## AND ITS LIGANDS PD-L## AND PD-L## (RAMSAY ET AL., 2012), IT SEEMS LOGICAL TO EXPLORE THE EFFECTS OF IMMUNOTHERAPY VIA THE USE OF PD-##/ PD-L##

  • Immunotherapy
  • North America
  • United States
  • Forecast
  • Pharmacyclics, Inc.
  • Early-Stage Pipeline Products in Non-Hodgkin's Lymphoma

TERM=RICER& RANK=##.

  • Epidemiology
  • Immunotherapy
  • Lymphoma
  • Therapy
  • Pharmacyclics, Inc.

Median ECOG was ## (##: ##, ##: ##, ##: ##). ## percent had PCNSL and ## percent SCNSL.

  • Immunotherapy
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Pharmacyclics, Inc.

It is also indicated for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, or in first line in the presence of ##p deletion or TP## mutation in patients unsuitable for chemo-

  • Immunotherapy
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Pharmacyclics, Inc.